Helix has partnered with Databricks to launch Helix Research Workspaces, a new trusted research environment designed to let scientists dig into population-scale genetic and clinical data while reducing infrastructure preparation. The platform pairs Helix's genomic database with Databricks' cloud infrastructure, aiming to strip away the specialized bioinformatics expertise and heavy lifting that population-scale genomic research typically demands.
The announcement, detailed in a release distributed via PR Newswire, frames the launch as a way to bring data and analysis tools into what Helix calls an easy-to-use, governed application. Helix Research Workspaces is built on the Databricks Data + AI Platform, and the companies say the Databricks ISV Built On program enables Helix to bring clinical and genomic data together in a governed, scalable environment. Approved Helix research partners get secure, governed access to compute, storage, and analysis tools through the platform, which is tied to Helix's operations in San Mateo, California.
James Lu, CEO and co-founder of Helix, framed the effort around cost and accessibility. “Data, compute and AI agents can make science faster, less expensive and accessible to more people,” Lu said, according to the same PR Newswire release. Sarah Branfman, global VP of ISV at Databricks, added that the partnership is about expanding access to population-scale clinicogenomic research to advance precision medicine.
What's Actually Inside the Platform
The Research Workspaces TRE bundles several tools researchers typically have to cobble together on their own. According to the release, it includes project-based notebooks and collaborative workspaces, data-access controls and monitoring, a built-in coding assistant for developing and refining analysis code, and a custom genomic-analysis toolkit built for large-scale genomic research. It also provides real-time visibility into analysis progress and compute costs, letting research teams track spending as projects run.
Helix says the platform is meant to support work like investigating potential drug targets, discovering biomarkers, and characterizing patient populations. Notably, the company positions the tool as useful for researchers who lack specialized bioinformatics support, allowing them to ask new questions, test ideas, and replicate findings without a dedicated technical team standing between them and the data.
Cohort Building and the Underlying Data
Research Workspaces builds on Helix Cohort Builder, a tool the company launched this year that lets researchers assemble targeted clinical and genomic cohorts either through a graphical interface or AI-assisted natural-language search, per the PR Newswire release. The idea is to let scientists narrow in on the specific patient populations relevant to their research questions before diving into deeper analysis.
That cohort-building capability draws on Helix's GenoSphere database, which the company describes on its own site as combining Exome+ genomic data with an average of more than 13 years of electronic health records, including medical and pharmacy claims, according to helix.com. The PR Newswire release states that Research Workspaces supports more than 550,000 linked GenoSphere clinicogenomic records, while Helix's own Research Network page separately describes the underlying network as built on Exome+ sequencing across more than 530,000 participants and roughly 20 health systems, according to Helix's Research Network page. The two figures come from different Helix sources and have not been reconciled.
Compute Costs and Broader Claims
Helix says researchers using the Research Workspaces TRE saw lower compute costs than when doing similar work on a different platform, per the company's own findings cited in the PR Newswire release. The release also states that AI capabilities built into the platform can significantly cut the total time needed to answer research questions. Helix describes its Research Network as the largest precision health network in the world, a characterization that reflects the company's own framing rather than independently verified rankings.
On its Research Network page, Helix describes the network itself as a large-scale scientific study designed to deepen understanding of the relationship between genetics, environment, and health outcomes, and notes that the evidence base deepens with every new patient sequenced. The company also points to outside research drawing on that network, including a 2025 medRxiv study on reducing variants of uncertain significance in hereditary germline testing through multi-institutional real-world evidence, cited on the same Helix page.
Part of a Wider Shift Toward Governed Data Environments
Helix's move fits into a broader pattern across health research, where trusted research environments have become a common way to let scientists work with sensitive data without moving it off secure infrastructure. Research published on pmc.ncbi.nlm.nih.gov notes that health research is shifting toward trusted research environments such as the All of Us Researcher Workbench and the UK Biobank. Similarly, a paper in Frontiers in Genetics describes federated clinical-genomic research models in which patient data is stored in trusted research environments or secure data environments while federated technology virtually links datasets across institutions.
Other companies have built comparable tools. DNAnexus markets its own cloud-native trusted research environment aimed at streamlining data integration and enabling secure collaboration, and separately promotes a population-genomics platform that combines genomic data with phenotypic and clinical information. In Canada, the CanPath research initiative has worked with Lifebit and AWS to build a secure, cloud-based trusted research environment for researcher access, according to CanPath's own description of the project.
Helix describes itself as an enterprise genomics platform and says it is building a centralized platform with applications spanning areas including partner operations. Whether Research Workspaces meaningfully changes the pace of clinicogenomic discovery will likely depend on adoption across the roughly 20 health systems tied to Helix's Research Network in the months ahead.
